Sarath Babu, MD
Internal Medicine · East Brunswick, NJNPI 1992744767
Payments from drug & device makers
Across 283 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Protega Pharmaceutials Inc$659
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$539
- Collegium Pharmaceutical, Inc.$465
- AstraZeneca$351
- Antares Pharma, Inc.$280
- Boehringer Ingelheim$229
- plus $2K from 28 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Speaking & faculty fees$52513%
- Food & beverage$3,51087%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Protega Pharmaceutials Inc | 12 | $659 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 44 | $539 |
| Collegium Pharmaceutical, Inc. | 39 | $465 |
| AstraZeneca | 25 | $351 |
| Antares Pharma, Inc. | 28 | $280 |
| Boehringer Ingelheim | 17 | $229 |
| Novo Nordisk | 17 | $229 |
| Pfizer | 19 | $188 |
| Lilly USA, LLC | 11 | $145 |
| Indivior Inc. | 11 | $130 |
| Merck | 8 | $110 |
| AbbVie(2 entities) | 8 | $107 |
| MDD US Operations, LLC | 6 | $83 |
| Johnson & Johnson | 6 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $54 |
| Novartis | 3 | $39 |
| Clarus Therapeutics Inc. | 3 | $39 |
| Forte Bio-pharma LLC | 1 | $29 |
| Biodelivery Sciences International, Inc. | 2 | $28 |
| Aytu Biopharma, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| Eisai Inc. | 2 | $24 |
| Alkermes, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Braeburn Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Orexo US, Inc. | 1 | $13 |
| USWM, LLC | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| GSK | 1 | $12 |
| Kaleo, Inc. | 1 | $12 |
How this compares
$4,047 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 290 | $195,965 |
| PercocetOxycodone Hcl/Acetaminophen | 30 | $101,140 |
| TrulicityDulaglutide | 56 | $75,021 |
| RoxybondOxycodone Hcl | 45 | $53,380 |
| OzempicSemaglutide | 38 | $41,469 |
| EliquisApixaban | 53 | $40,748 |
| Xtampza ErOxycodone Myristate | 50 | $34,916 |
| Nucynta ErTapentadol Hcl | 25 | $30,128 |
| TrulancePlecanatide | 27 | $27,289 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 347 | $26,374 |
| MounjaroTirzepatide | 23 | $24,449 |
| XareltoRivaroxaban | 35 | $23,643 |
| JardianceEmpagliflozin | 22 | $22,947 |
| JanuviaSitagliptin Phosphate | 13 | $20,363 |
| Oxycodone Hcl | 1,202 | $17,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $145 | $99,47079 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er | $465 | $65,04575 claims |
| Protega Pharmaceutials IncRoxybond | $659 | $53,38045 claims |
| Novo NordiskOzempic | $229 | $41,46938 claims |
| PfizerEliquis | $188 | $40,74853 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl, Buprenorphine | $12 | $32,482507 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $539 | $27,28927 claims |
| Johnson & JohnsonXarelto | $78 | $23,64335 claims |
| Boehringer IngelheimJardiance | $229 | $22,94722 claims |
| MerckJanuvia | $110 | $20,36313 claims |
| Antares Pharma, Inc.Xyosted | $280 | $10,45617 claims |
| Orexo US, Inc.Zubsolv | $13 | $7,82626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in East Brunswick
- Jenny LiuEast Brunswick$609K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.